[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Fagan et al., 2009 - Google Patents

Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's …

Fagan et al., 2009

View PDF
Document ID
7570861346820996701
Author
Fagan A
Mintun M
Shah A
Aldea P
Roe C
Mach R
Marcus D
Morris J
Holtzman D
Publication year
Publication venue
EMBO molecular medicine

External Links

Snippet

Alzheimer's disease (AD) pathology is estimated to develop many years before detectable cognitive decline. Fluid and imaging biomarkers may identify people in early symptomatic and even preclinical stages, possibly when potential treatments can best preserve cognitive …
Continue reading at www.embopress.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—G01N2333/4701
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment; Prognosis

Similar Documents

Publication Publication Date Title
Fagan et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease
Shaw et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease
Delacourte et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease
d’Abramo et al. Significance of blood and cerebrospinal fluid biomarkers for Alzheimer’s disease: sensitivity, specificity and potential for clinical use
Lewczuk et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Vemuri et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease
Skillbäck et al. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia
Sunderland et al. Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: the effect of APOE ε4 allele
Blennow et al. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
Toledo et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
Shaw et al. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
Blennow et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
De Leon et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease
Hampel et al. Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment
Schoonenboom et al. Amyloid β (1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease
Henry et al. The development of effective biomarkers for Alzheimer's disease: a review
Lewczuk et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study
Lewczuk et al. Clinical significance of fluid biomarkers in Alzheimer’s Disease
Rosenmann CSF biomarkers for amyloid and tau pathology in Alzheimer's disease
Therriault et al. Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Hu et al. Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults
Ma et al. Reduction of SorLA/LR11, a sorting protein limiting β-amyloid production, in alzheimer disease cerebrospinal fluid
Ibach et al. Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample
Sancesario et al. Diagnosis of neurodegenerative dementia: where do we stand, now?
Tijms et al. Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals